Literature DB >> 18562222

Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.

Deepika Dhawan1, José A Ramos-Vara, Jane C Stewart, Rong Zheng, Deborah W Knapp.   

Abstract

OBJECTIVES: Urinary bladder cancer is the fifth most common form of cancer in humans in the United States. Urinary bladder cancer also occurs in pet dogs, and naturally-occurring bladder cancer in pet dogs very closely resembles invasive bladder cancer (intermediate to high grade invasive transitional cell carcinoma, InvTCC) in humans. Pet dogs with InvTCC offer a highly relevant resource for preclinical studies in bladder cancer. For translational research in which findings are moved from in vitro experiments through in vivo studies in dogs to human trials, access to human and canine bladder cancer cell lines is important. Cell lines derived from canine InvTCC have been lacking. Here we describe eight such cell lines.
MATERIALS AND METHODS: Eight cell lines were established from canine InvTCC. Cells were characterized using immunocytochemistry, evaluated for anchorage independent growth in soft agar, and assessed for tumorigenicity in athymic mice. Western blotting was used to identify expression of proteins of interest in human InvTCC.
RESULTS: The cell lines were confirmed to be of epithelial origin by their expression of cytokeratin and E-cadherin. Seven cell lines were found to be tumorigenic in athymic mice, and 4 of these cell lines grew in an anchorage independent manner. The cell lines expressed several proteins of interest associated with bladder cancer prognosis and progression in humans, including p53, cox-2, and pRb protein.
CONCLUSIONS: These established cell lines can be used for comparative bladder cancer research and to evaluate new therapy approaches in vitro prior to in vivo testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562222     DOI: 10.1016/j.urolonc.2008.02.015

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  24 in total

1.  Canine urothelial carcinoma: genomically aberrant and comparatively relevant.

Authors:  S G Shapiro; S Raghunath; C Williams; A A Motsinger-Reif; J M Cullen; T Liu; D Albertson; M Ruvolo; A Bergstrom Lucas; J Jin; D W Knapp; J D Schiffman; M Breen
Journal:  Chromosome Res       Date:  2015-03-18       Impact factor: 5.239

Review 2.  Animal Models of Bone Metastasis.

Authors:  J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol
Journal:  Vet Pathol       Date:  2015-05-28       Impact factor: 2.221

3.  Coincidence of v-raf murine sarcoma viral oncogene homolog B mutation (V595E) with phosphorylated v-raf murine sarcoma viral oncogene homolog B in urothelial carcinoma in dogs.

Authors:  Hirofumi Yamasaki; Yosuke Uematsu; Yuhei Hayashi; Masao Yamashita; Meina Tei; Kazuyuki Uchida; Kenichiro Ono; Hidehiro Hirao
Journal:  Can J Vet Res       Date:  2022-10       Impact factor: 0.897

4.  Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.

Authors:  Brennan Decker; Heidi G Parker; Deepika Dhawan; Erika M Kwon; Eric Karlins; Brian W Davis; José A Ramos-Vara; Patty L Bonney; Elizabeth A McNiel; Deborah W Knapp; Elaine A Ostrander
Journal:  Mol Cancer Res       Date:  2015-03-12       Impact factor: 5.852

5.  Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand.

Authors:  Tzu-yin Lin; Hongyong Zhang; Sisi Wang; Li Xie; Bin Li; Carlos O Rodriguez; Ralph de Vere White; Chong-xian Pan
Journal:  Mol Cancer       Date:  2011-01-27       Impact factor: 27.401

Review 6.  Preclinical Models for Bladder Cancer Research.

Authors:  Shaoming Zhu; Zheng Zhu; Ai-Hong Ma; Guru P Sonpavde; Fan Cheng; Chong-Xian Pan
Journal:  Hematol Oncol Clin North Am       Date:  2021-04-16       Impact factor: 2.861

7.  Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer.

Authors:  Tzu-Yin Lin; Hongyong Zhang; Juntao Luo; Yuanpei Li; Tingjuan Gao; Primo N Lara; Ralph de Vere White; Kit S Lam; Chong-Xian Pan
Journal:  Int J Nanomedicine       Date:  2012-06-06

8.  Epidermal growth factor receptor expression in canine transitional cell carcinoma.

Authors:  Kiwamu Hanazono; Shinya Fukumoto; Yoshio Kawamura; Yoshifumi Endo; Tsuyoshi Kadosawa; Hidetomo Iwano; Tsuyoshi Uchide
Journal:  J Vet Med Sci       Date:  2014-09-16       Impact factor: 1.267

9.  A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.

Authors:  Kusum Rathore; Maria Cekanova
Journal:  Drug Des Devel Ther       Date:  2015-09-25       Impact factor: 4.162

10.  A cultured approach to canine urothelial carcinoma: molecular characterization of five cell lines.

Authors:  S G Shapiro; D W Knapp; Matthew Breen
Journal:  Canine Genet Epidemiol       Date:  2015-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.